Vivimed Labs Limited — Important, 14-11-2024: Financial Result Updates

**Consolidated Financial Results Summary**

Vivimed Labs Limited reported consolidated revenue of ₹1,490.71 crore for the year ended March 2024, showing a decline of about 20.69% from ₹1,880.67 crore in the previous fiscal year. This drop can be attributed to challenges in the Pharma business, which faced reduced demand and operational inefficiencies, significantly impacting overall revenue.

The company's overall net loss for the year amounted to ₹533.68 crore, an improvement from a loss of ₹2,947.48 crore in FY 2022-23. This year-over-year reduction in losses reflects a potential recovery plan and cost management strategies being implemented. The Earnings Per Share (EPS) stood at ₹(3.49), better than ₹(17.84) a year earlier.

Operational costs showed a decrease of approximately 16% compared to the previous year, suggesting effective cost control measures, although challenges remain due to high financing expenses amounting to ₹336.91 crore.

On the balance sheet, total assets decreased to ₹9,509.11 crore from ₹9,950.50 crore. The company has cash and cash equivalents totaling ₹20.26 crore, down from ₹37.62 crore, reflecting cash flow pressures. However, it successfully generated positive cash flow from investing activities, with net cash inflows of ₹998.26 crore from asset divestitures.

Strategically, Vivimed appears focused on revitalizing its core business segments while managing its debt levels. The sentiment in the market is cautious, given the history of losses and liquidity issues but may turn positive if the company's restructuring plan yields results.

Investor Insight: Hold. The company is on a path of recovery, but ongoing management of operational costs and revenue generation remains critical. Watch for improvement in key segments and potential market recovery.